Biointron Weekly Reports

News

Biointron is proud to announce a strategic partnership with FatiAbGen Inc. , a leading biotechnology firm that focuses on antibody-based therapeutics. As the newly appointed Korean distributor for Biointron, FatiAbGen will be at the forefront of delivering Biointron’s products to the Korean market. Furthermore, this partnership also focuses on fostering innovation and expanding market reach in the dynamic landscape of the Korean biotech industry. ?

Thank you to everyone who came to meet the Biointron team at Biologics 2024 in London, UK, last week! It was a truly insightful event, with attendees and speakers in the biologics, pharmaceutical, healthcare, and research fields from all over Europe and the rest of the world. Read a summary of the key trends highlighted at the conference here.?

In our latest episode of the Antibody Basics video series (Part 5), we describe the function, structure, and formats of common antibody fragments such as Fab, F(ab')2, and Fc. We also show their importance in diagnostic and therapeutic applications, with future potential directions. Watch it now.?

This Week’s News?

• New discovery of human monoclonal antibodies targeting the underside of the neuraminidase (NA) globular head domain. The NA protein is common among several influenza subtypes, including H3N2.
• FDA approves antibody-drug conjugate Besponsa (inotuzumab ozogamicin) to treat pediatric patients 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.
• Novel FDA drug approval of Tevimbra (tislelizumab) to treat advanced or metastatic esophageal squamous cell carcinoma (ESCC) after prior chemotherapy. Tislelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody (mAb) which minimizes binding to macrophage Fcγ receptors.

Trends – Esophageal Cancer Antibody Success

Last week on March 14, the FDA finally greenlit BeiGene ’s monoclonal antibody Tevimbra (tislelizumab) to treat advanced or metastatic esophageal squamous cell carcinoma (ESCC) after prior chemotherapy. Tislelizumab is a humanized IgG4 anti-PD-1 mAb which minimizes binding to macrophage Fcγ receptors, thus facilitating the patient’s immune cells to recognize and fight tumors.?

Esophageal cancer is the sixth most common cause of cancer fatalities in the world, with over two-thirds of patients having advanced or metastatic disease at the time of diagnosis. Several clinical trials have taken place for use as both a monotherapy and in combination with other regimens, and over 750,000 individuals have been prescribed. Currently, Tevimbra is also undergoing a review for a BLA (Biologics License Application) for first-line ESCC patients, and and for gastric or gastroesophageal junction adenocarcinoma.?

In the research space, Chen et al. published a paper in Nature Communications this month about the predictive role of ctDNA in ESCC?receiving definitive chemoradiotherapy combined with toripalimab. Toripalimab is an mAb approved for the treatment of melanoma and nasopharyngeal carcinoma. It is a recombinant humanized programmed cell death protein 1 (PD-1) IgG4 that acts as a checkpoint inhibitor.?

Similarly, a recent report by Yang et al. demonstrated that neoadjuvant camrelizumab combined with chemotherapy showed promising efficacy in locally advanced ESCC. Camrelizumab is also an anti-PD-1 immune checkpoint inhibitor developed by Jiangsu HengRui Medicine. Meanwhile, Arcus Biosciences is developing a monoclonal antibody AB-598 for esophageal cancer, which is in Phase I trials. ?

Overall, Tevimbra’s breakthrough may have significant impacts to the cancer space, including a new standard of care for patients, improved chances of survival, more options for treatment choice, and a stronger sense of hope and positivity.?

Promotions

Get ready for a fantastic adventure at AACR with the “Great Dr. Young Hunt”! Score a pair of AirPods or a Google Speaker by keeping your eyes peeled on our social media channels and around the AACR conference for Dr. Young stickers to collect. Swing by?Biointron Booth #746 on the last day with your collection to take home your goodies!?For more info click here.

Biointron offers a new choice for your small-scale antibody expression rush needs: RushMab? Small-Scale Antibody Expression Packages.?

?? Designed to be cost-effective and time-saving?

? As fast as 8 days?

?? More than 5000 samples?

?? Explore different packages from Super, Standard, and Mini

Upcoming Events?

Coming up next month is the AACR ( American Association for Cancer Research ) Annual Meeting 2024, on April 5-10. We hope you can join us there at the San Diego Convention Center in California. The event will gather scientists, clinicians, survivors, patients, and advocates in the cancer research community, to share the latest advances in oncology. Don’t miss out and meet us at Booth #746 or schedule a one-to-one meeting with our team here!?

Also happening soon is the Festival of Biologics San Diego (FOB) on April 15-17, 2024, at the San Diego Convention Center, CA! Join Biointron at this hub for groundbreaking discussions and innovations in the biologics sector. Our team is eager to meet fellow professionals, thought leaders, and enthusiasts. Find us at Booth #240 or register for a 1-on-1 meeting here. ?

New Products?

• 2023 Antibody Industry Report?
• CHOK1-FUT8 Afucosylated Antibody Expression Platform?
• Small-Scale Packages-RushMab??

Learn more about Biointron at www.biointron.com, or contact us at [email protected] and +1 (732) 515-4766.